NRX Pharmaceuticals, headquartered in Wilmington, Delaware, is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, including its lead compounds NRX-100 and NRX-101. The company went public on November 20, 2017, and is developing therapies targeting bipolar depression, chronic pain, and PTSD.
Jonathan C Javitt bought 40,000 shares of NRXP on 17 December at $1.17 per share, worth a total of $47K. They now own 84,634 NRXP shares, or a 90% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
